AIM: To study whether CCR5Delta32 mutation was associated with viral infection and severity of liver disease. METHODS: Two hundred and fifty two histologically proven, chronic HCV patients (mean age: 41 +/- 14 years; M/F: 164/88) were genotyped. PCR based genotyping of 32 bp deletion at the CCR5 locus was done. Four-hundred and eight matched healthy controls were studied to assess susceptibility to HCV infection. To assess correlation of immune gene polymorphism with severity of HCV related liver disease, patients with chronic HCV infection were divided into those with a fibrosis score of <= 2 (mild) or > 2 (severe) and histological activity index (HAI) of <= 5 or > 5. For correlation between CCR5Delta32 mutations and response to therapy, 129 patients who completed therapy were evaluated. RESULTS: The majority (89.4%) of the patients were infected with genotype 3. The frequency of homozygous CCR5Delta32 mutants was comparable to HCV patients as compared to the healthy controls (0.7% vs 0%, P = 0.1). Further more, the frequency of CCR5Delta32 mutation was comparable in patients with mild or severe liver disease. (P = NS). There was also no association observed with response to therapy and CCR5Delta32 mutation. CONCLUSION: CCR5Delta32 mutation does not have a role in disease susceptibility, severity or response to therapy in patients with chronic hepatitis C infection.
AIM: To study whether CCR5Delta32 mutation was associated with viral infection and severity of liver disease. METHODS: Two hundred and fifty two histologically proven, chronic HCV patients (mean age: 41 +/- 14 years; M/F: 164/88) were genotyped. PCR based genotyping of 32 bp deletion at the CCR5 locus was done. Four-hundred and eight matched healthy controls were studied to assess susceptibility to HCV infection. To assess correlation of immune gene polymorphism with severity of HCV related liver disease, patients with chronic HCV infection were divided into those with a fibrosis score of <= 2 (mild) or > 2 (severe) and histological activity index (HAI) of <= 5 or > 5. For correlation between CCR5Delta32 mutations and response to therapy, 129 patients who completed therapy were evaluated. RESULTS: The majority (89.4%) of the patients were infected with genotype 3. The frequency of homozygous CCR5Delta32 mutants was comparable to HCV patients as compared to the healthy controls (0.7% vs 0%, P = 0.1). Further more, the frequency of CCR5Delta32 mutation was comparable in patients with mild or severe liver disease. (P = NS). There was also no association observed with response to therapy and CCR5Delta32 mutation. CONCLUSION: CCR5Delta32 mutation does not have a role in disease susceptibility, severity or response to therapy in patients with chronic hepatitis C infection.
Authors: C Zavaglia; M Martinetti; E Silini; R Bottelli; C Daielli; M Asti; A Airoldi; L Salvaneschi; M U Mondelli; G Ideo Journal: J Hepatol Date: 1998-01 Impact factor: 25.083
Authors: P Garred; H O Madsen; J Petersen; H Marquart; T M Hansen; S Freiesleben Sørensen; B Volck; A Svejgaard; V Andersen Journal: J Rheumatol Date: 1998-08 Impact factor: 4.666
Authors: H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape Journal: Lancet Date: 1995-10-14 Impact factor: 79.321
Authors: Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies Journal: Virus Res Date: 2020-05-30 Impact factor: 3.303
Authors: Amal Abdul-rasheed El-Moamly; Mohamed Aly El-Sweify; Rafiaa M Rashad; Esam M Abdalla; Mostafa M Ragheb; Mohamed M Awad Journal: Parasitol Res Date: 2013-03-21 Impact factor: 2.383
Authors: Isabelle Morard; Sophie Clément; Alexandra Calmy; Alessandra Mangia; Andrea Cerny; Andrea De Gottardi; Meri Gorgievski; Markus Heim; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; David Semela; Stéphanie Pascarella; Pierre-Yves Bochud; Franco Negro Journal: PLoS One Date: 2014-09-05 Impact factor: 3.240